10x Genomics, Bioptimus, and Broad Clinical Labs announced a partnership to launch the Spatial Tissue Embedding Learning Atlas (STELA), a global effort to generate high‑resolution spatial data from up to 100,000 patient specimens across the United States, Europe, and Asia. The collaboration will use 10x Genomics’ Xenium spatial transcriptomics platform as the core technology, enabling subcellular mapping of up to 5,000 genes per sample.
STELA will integrate Xenium’s 5,000‑gene panel with matched histopathology imaging, multi‑omics data—including genomics, transcriptomics, and proteomics—and longitudinal clinical records. The resulting atlas will be the world’s largest clinically linked, spatially profiled, multimodal patient data resource, providing a foundation for AI‑driven insights into disease mechanisms and therapeutic responses.
The partnership comes on the heels of 10x Genomics’ Q4 2025 earnings, in which the company reported revenue of $166 million—up 1% from the same quarter in 2024—and an EPS of –$0.13, beating analyst expectations of –$0.10. The beat was driven by strong demand for consumables, which offset a decline in instrument revenue, and by disciplined cost control that helped maintain margins. Management highlighted the partnership as a key driver of future growth, noting that the expanded reach of Xenium into large‑scale, clinically relevant studies will accelerate adoption in precision medicine and drug discovery.
Bioptimus co‑founder and CEO Jean Philippe Vert said, "STELA is the fuel to power M‑Optimus, allowing us to map the intricate interactions between cells and tissues, across indications, at unprecedented scales, unlocking a new era of precision medicine." 10x Genomics CEO Serge Saxonov added, "By enabling spatial profiling at unprecedented scale, STELA will generate foundational datasets that allow researchers to connect the underlying biology with disease outcomes."
Analysts have responded positively to the partnership, citing the strong financial performance of 10x Genomics and the strategic fit of STELA with the company’s long‑term vision for spatial biology. The collaboration positions 10x Genomics to expand the reach of Xenium beyond individual research labs to a coordinated, multi‑institutional effort, while Bioptimus gains access to a vast, high‑quality data set to train its world‑model for biology. Broad Clinical Labs’ expertise in high‑throughput workflows ensures the scalability and quality of data generation, reinforcing the initiative’s potential to transform precision medicine and drug discovery.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.